{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:30:28Z","timestamp":1792801828172,"version":"4.5.0"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100012940","name":"Universit\u00e4tsklinikum T\u00fcbingen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012940","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Artemisinin-based Combination Therapy (ACT) has contributed to the reduction of malaria burden in sub-Saharan Africa. However, the number of global cases has risen since 2015. Resistances to artemisinin reported from Southeast Asia and recently emerged in sub-Saharan Africa might threaten ACT efficacy. We conducted a systematic review and meta-analysis on ACT efficacy trends in sub-Saharan Africa from January 2010 to December 2024.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We systematically searched PubMed\/Medline and Scopus for studies published between 2010 and 2024 that met the World Health Organisation (WHO) criteria for therapeutic efficacy studies. Two reviewers have independently assessed the eligibility criteria and extracted data. ACT efficacy was measured using the PCR-corrected Adequate Clinical and Parasitological Response (ACPR) at day 28 or 42. Meta-analysis was conducted using R.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The meta-analysis included 116 studies with a total of 17,341 participants for artemether-lumefantrine (AL), 8,855 for artesunate-amodiaquine (AS-AQ), 5,544 for dihydroartemisinin-piperaquine (DHA-PPQ), and 346 for artesunate-pyronaridine (AS-PY). Over the period under review, from 2010 to 2024, the PCR-corrected ACPR for AS-AQ, DHA-PPQ, and AS-PY remained above 90% across sub-Saharan Africa. For AL, the PCR-corrected ACPR remained high between 2010 and 2014, consistently exceeding 90% (range: 91\u2013100%). However, from 2015 to 2024, the efficacy showed greater variability, with PCR-corrected ACPR values ranging from 74% to 100%. Notably, this efficacy dropped below the 90% threshold in several countries, including Kenya (2017), Burkina Faso (2018), Uganda (2019), and Nigeria (2020).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>While AS-AQ, DHA-PPQ, and AS-PY have maintained high efficacy over time in sub-Saharan Africa, there is a concern about the declining efficacy of AL in some West and East African countries. Our findings suggest that AS-PY could be a promising candidate for inclusion in first-line malaria treatments to address the declining efficacy of AL. Continuous monitoring of ACT efficacy, innovative and efficient control strategies are crucial to prevent the spread of antimalarial drug resistance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Registration<\/jats:title>\n                    <jats:p>PROSPERO number CRD42023432718<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-025-12130-8","type":"journal-article","created":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T16:34:38Z","timestamp":1764088478000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Spatio-temporal trends of artemisinin-based combination therapy efficacy from 2010 to 2024 in sub-Saharan Africa: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"25","author":[{"given":"Francis Emmanuel Towanou","family":"Bohissou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gu\u00e9tawend\u00e9 Job Wilfried","family":"Nassa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Sondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toussaint","family":"Rouamba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berenger","family":"Kabor\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Asua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Held","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Halidou","family":"Tinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,25]]},"reference":[{"key":"12130_CR1","unstructured":"World malaria report 2024 n.d. Accessed March 12, 2025. https:\/\/www.who.int\/teams\/global-malaria-programme\/reports\/world-malaria-report-2024."},{"key":"12130_CR2","unstructured":"Artemisinin resistance and artemisinin-based combination therapy efficacy (December 2019) n.d."},{"key":"12130_CR3","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1056\/NEJMc0805011","volume":"359","author":"H Noedl","year":"2008","unstructured":"Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, Fukuda MM, et al. Evidence of artemisinin-resistant malaria in western Cambodia. N Engl J Med. 2008;359:2619\u201320. https:\/\/doi.org\/10.1056\/NEJMc0805011.","journal-title":"N Engl J Med"},{"key":"12130_CR4","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1056\/NEJMoa0808859","volume":"361","author":"AM Dondorp","year":"2009","unstructured":"Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2009;361:455\u201367. https:\/\/doi.org\/10.1056\/NEJMoa0808859.","journal-title":"N Engl J Med"},{"key":"12130_CR5","doi-asserted-by":"publisher","first-page":"e591","DOI":"10.1016\/S1473-3099(24)00141-5","volume":"24","author":"PJ Rosenthal","year":"2024","unstructured":"Rosenthal PJ, Asua V, Bailey JA, Conrad MD, Ishengoma DS, Kamya MR, et al. The emergence of artemisinin partial resistance in Africa: how do we respond? Lancet Infect Dis. 2024;24:e591\u2013600. https:\/\/doi.org\/10.1016\/S1473-3099(24)00141-5.","journal-title":"Lancet Infect Dis"},{"key":"12130_CR6","first-page":"1352","volume":"211","author":"E Kamau","year":"2015","unstructured":"Kamau E, Campino S, Amenga-Etego L, Drury E, Ishengoma D, Johnson K, et al. K13-propeller polymorphisms in Plasmodium falciparum parasites from Sub-Saharan Africa. J Infect Dis. 2015;211:1352\u201355.","journal-title":"The J Infect Dis"},{"key":"12130_CR7","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1056\/NEJMoa1513137","volume":"374","author":"D M\u00e9nard","year":"2016","unstructured":"M\u00e9nard D, Khim N, Beghain J, Adegnika AA, Shafiul-Alam M, Amodu O, et al. A worldwide map of plasmodium falciparum K13-propeller polymorphisms. N Engl J Med. 2016;374:2453\u201364. https:\/\/doi.org\/10.1056\/NEJMoa1513137.","journal-title":"N Engl J Med"},{"key":"12130_CR8","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.ijpddr.2021.06.001","volume":"16","author":"L Ndwiga","year":"2021","unstructured":"Ndwiga L, Kimenyi KM, Wamae K, Osoti V, Akinyi M, Omedo I, et al. A review of the frequencies of Plasmodium falciparum Kelch 13 artemisinin resistance mutations in Africa. Int J Parasitol Drugs Drug Resist. 2021;16:155\u201361. https:\/\/doi.org\/10.1016\/j.ijpddr.2021.06.001.","journal-title":"Int J Parasitol Drugs Drug Resist"},{"key":"12130_CR9","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/s41579-024-01008-2","volume":"22","author":"PJ Rosenthal","year":"2024","unstructured":"Rosenthal PJ, Asua V, Conrad MD. Emergence, transmission dynamics and mechanisms of artemisinin partial resistance in malaria parasites in Africa. Nat Rev Microbiol. 2024;22:373\u201384. https:\/\/doi.org\/10.1038\/s41579-024-01008-2.","journal-title":"Nat Rev Microbiol"},{"key":"12130_CR10","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/S1473-3099(21)00142-0","volume":"21","author":"A Uwimana","year":"2021","unstructured":"Uwimana A, Umulisa N, Venkatesan M, Svigel SS, Zhou Z, Munyaneza T, et al. Association of plasmodium falciparum kelch13 R561H genotypes with delayed parasite clearance in Rwanda: an open-label, single-arm, multicentre, therapeutic efficacy study. Lancet Infect Dis. 2021;21:1120\u201328. https:\/\/doi.org\/10.1016\/S1473-3099(21)00142-0.","journal-title":"Lancet Infect Dis"},{"key":"12130_CR11","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ijid.2023.11.026","volume":"139","author":"G Mesia Kahunu","year":"2024","unstructured":"Mesia Kahunu G, Wellmann Thomsen S, Wellmann Thomsen L, Muhindo Mavoko H, Mitashi Mulopo P, Filtenborg Hocke E, et al. Identification of the PfK13 mutations R561H and P441L in the democratic Republic of Congo. Int J Infect Dis IJID Off Publ Int Soc Infect Dis. 2024;139:41\u201349. https:\/\/doi.org\/10.1016\/j.ijid.2023.11.026.","journal-title":"Int J Infect Dis IJID Off Publ Int Soc Infect Dis"},{"key":"12130_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2024.12.019","author":"W Abebe","year":"2024","unstructured":"Abebe W, Mekuanint A, Asmare Z, Woldesenbet D, Mihret Y, Setegn A, et al. Prevalence of molecular markers of chloroquine resistance in malaria parasites in East Africa: a systematic review and meta-analysis. J Glob Antimicrob Resist. 2024. https:\/\/doi.org\/10.1016\/j.jgar.2024.12.019.","journal-title":"J Glob Antimicrob Resist"},{"key":"12130_CR13","doi-asserted-by":"publisher","first-page":"1167220","DOI":"10.3389\/fcimb.2023.1167220","volume":"13","author":"S Wang","year":"2023","unstructured":"Wang S, Huang F, Yan H, Yin J, Xia Z. A review of malaria molecular markers for drug resistance in Plasmodium falciparum and Plasmodium vivax in China. Front Cell Infect Microbiol. 2023;13:1167220. https:\/\/doi.org\/10.3389\/fcimb.2023.1167220.","journal-title":"Front Cell Infect Microbiol"},{"key":"12130_CR14","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s12936-024-04848-8","volume":"23","author":"A Assefa","year":"2024","unstructured":"Assefa A, Fola AA, Tasew G. Emergence of plasmodium falciparum strains with artemisinin partial resistance in East Africa and the Horn of Africa: is there a need to panic? Malar J. 2024;23:34. https:\/\/doi.org\/10.1186\/s12936-024-04848-8.","journal-title":"Malar J"},{"key":"12130_CR15","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1111\/mec.15706","volume":"30","author":"KA Moser","year":"2021","unstructured":"Moser KA, Madebe RA, Aydemir O, Chiduo MG, Mandara CI, Rumisha SF, et al. Describing the current status of Plasmodium falciparum population structure and drug resistance within mainland Tanzania using molecular inversion probes. Mol Ecol. 2021;30:100\u201313. https:\/\/doi.org\/10.1111\/mec.15706.","journal-title":"Mol Ecol"},{"key":"12130_CR16","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1038\/s41591-020-1005-2","volume":"26","author":"A Uwimana","year":"2020","unstructured":"Uwimana A, Legrand E, Stokes BH, Ndikumana J-L, Warsame M, Umulisa N, et al. Emergence and clonal expansion of in vitro artemisinin-resistant plasmodium falciparum kelch13 R561H mutant parasites in Rwanda. Nat Med. 2020;26:1602\u201308. https:\/\/doi.org\/10.1038\/s41591-020-1005-2.","journal-title":"Nat Med"},{"key":"12130_CR17","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1056\/NEJMoa2211803","volume":"389","author":"MD Conrad","year":"2023","unstructured":"Conrad MD, Asua V, Garg S, Giesbrecht D, Niar\u00e9 K, Smith S, et al. Evolution of partial resistance to artemisinins in malaria parasites in Uganda. N Engl J Med. 2023;389:722\u201332. https:\/\/doi.org\/10.1056\/NEJMoa2211803.","journal-title":"N Engl J Med"},{"key":"12130_CR18","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1038\/s41564-023-01461-4","volume":"8","author":"AA Fola","year":"2023","unstructured":"Fola AA, Feleke SM, Mohammed H, Brhane BG, Hennelly CM, Assefa A, et al. Plasmodium falciparum resistant to artemisinin and diagnostics have emerged in Ethiopia. Nat Microbiol. 2023;8:1911\u201319. https:\/\/doi.org\/10.1038\/s41564-023-01461-4.","journal-title":"Nat Microbiol"},{"key":"12130_CR19","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1056\/NEJMoa2210956","volume":"389","author":"S Mihreteab","year":"2023","unstructured":"Mihreteab S, Platon L, Berhane A, Stokes BH, Warsame M, Campagne P, et al. Increasing prevalence of artemisinin-resistant HRP2-negative malaria in Eritrea. N Engl J Med. 2023;389:1191\u2013202. https:\/\/doi.org\/10.1056\/NEJMoa2210956.","journal-title":"N Engl J Med"},{"key":"12130_CR20","doi-asserted-by":"publisher","first-page":"e01949","DOI":"10.1128\/AAC.01949-20","volume":"65","author":"PR Dimbu","year":"2021","unstructured":"Dimbu PR, Horth R, C\u00e2ndido ALM, Ferreira CM, Caquece F, Garcia LEA, et al. Continued Low Efficacy of Artemether-Lumefantrine in Angola in 2019. Antimicrob Agents Chemother. 2021;65:e01949\u201320. https:\/\/doi.org\/10.1128\/AAC.01949-20.","journal-title":"Antimicrob Agents Chemother"},{"key":"12130_CR21","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.4269\/ajtmh.21-0214","volume":"105","author":"LF Moriarty","year":"2021","unstructured":"Moriarty LF, Nkoli PM, Likwela JL, Mulopo PM, Sompwe EM, Rika JM, et al. Therapeutic efficacy of artemisinin-based combination therapies in Democratic Republic of the Congo and investigation of molecular markers of antimalarial resistance. Am J Trop Med Hyg. 2021;105:1067\u201375. https:\/\/doi.org\/10.4269\/ajtmh.21-0214.","journal-title":"Am J Trop Med Hyg"},{"key":"12130_CR22","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12936-021-03585-6","volume":"20","author":"A Gansan\u00e9","year":"2021","unstructured":"Gansan\u00e9 A, Moriarty LF, M\u00e9nard D, Yerbanga I, Ouedraogo E, Sondo P, et al. Anti-malarial efficacy and resistance monitoring of artemether-lumefantrine and dihydroartemisinin-piperaquine shows inadequate efficacy in children in Burkina Faso, 2017\u20132018. Malar J. 2021;20:48. https:\/\/doi.org\/10.1186\/s12936-021-03585-6.","journal-title":"Malar J"},{"key":"12130_CR23","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1186\/s12936-021-04021-5","volume":"20","author":"C Ebong","year":"2021","unstructured":"Ebong C, Sserwanga A, Namuganga JF, Kapisi J, Mpimbaza A, Gonahasa S, et al. Efficacy and safety of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated plasmodium falciparum malaria and prevalence of molecular markers associated with artemisinin and partner drug resistance in Uganda. Malar J. 2021;20:484. https:\/\/doi.org\/10.1186\/s12936-021-04021-5.","journal-title":"Malar J"},{"key":"12130_CR24","unstructured":"Report on antimalarial drug efficacy, resistance and response: 10 years of surveillance (2010-2019) n.d. accessed March 15, 2023. https:\/\/www.who.int\/publications-detail-redirect\/9789240012813."},{"key":"12130_CR25","doi-asserted-by":"publisher","first-page":"e26005","DOI":"10.1371\/journal.pone.0026005","volume":"6","author":"S Borrmann","year":"2011","unstructured":"Borrmann S, Sasi P, Mwai L, Bashraheil M, Abdallah A, Muriithi S, et al. Declining responsiveness of plasmodium falciparum infections to artemisinin-based combination treatments on the Kenyan coast. PLoS One. 2011;6:e26005. https:\/\/doi.org\/10.1371\/journal.pone.0026005.","journal-title":"PLoS One"},{"key":"12130_CR26","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.3201\/eid2107.150213","volume":"21","author":"M Hawkes","year":"2015","unstructured":"Hawkes M, Conroy AL, Opoka RO, Namasopo S, Zhong K, Liles WC, et al. Slow clearance of plasmodium falciparum in severe pediatric malaria, Uganda, 2011-2013. Emerg Infect Dis. 2015;21:1237\u201339. https:\/\/doi.org\/10.3201\/eid2107.150213.","journal-title":"Emerg. Infect. Dis"},{"key":"12130_CR27","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1186\/s12936-015-1018-3","volume":"14","author":"K Kiaco","year":"2015","unstructured":"Kiaco K, Teixeira J, Machado M, Do Ros\u00e1rio V, Lopes D. Evaluation of artemether-lumefantrine efficacy in the treatment of uncomplicated malaria and its association with pfmdr1, pfatpase6 and K13-propeller polymorphisms in Luanda, Angola. Malar J. 2015;14:504. https:\/\/doi.org\/10.1186\/s12936-015-1018-3.","journal-title":"Malar J"},{"key":"12130_CR28","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1186\/s12936-020-03446-8","volume":"19","author":"G Rathmes","year":"2020","unstructured":"Rathmes G, Rumisha SF, Lucas TCD, Twohig KA, Python A, Nguyen M, et al. Global estimation of anti-malarial drug effectiveness for the treatment of uncomplicated plasmodium falciparum malaria 1991\u20132019. Malar J. 2020;19:374. https:\/\/doi.org\/10.1186\/s12936-020-03446-8.","journal-title":"Malar J"},{"key":"12130_CR29","doi-asserted-by":"publisher","first-page":"101919","DOI":"10.1016\/j.parint.2019.04.016","volume":"74","author":"PG Mathenge","year":"2020","unstructured":"Mathenge PG, Low SK, Vuong NL, Mohamed MYF, Faraj HA, Alieldin GI, et al. Efficacy and resistance of different artemisinin-based combination therapies: a systematic review and network meta-analysis. Parasitol Int. 2020;74:101919. https:\/\/doi.org\/10.1016\/j.parint.2019.04.016.","journal-title":"Parasitol Int"},{"key":"12130_CR30","doi-asserted-by":"publisher","first-page":"7371681","DOI":"10.1155\/2020\/7371681","volume":"2020","author":"A Derbie","year":"2020","unstructured":"Derbie A, Mekonnen D, Adugna M, Yeshitela B, Woldeamanuel Y, Abebe T. Therapeutic efficacy of artemether-lumefantrine (Coartem\u00ae) for the treatment of uncomplicated falciparum malaria in Africa: a systematic review. J Parasitol Res. 2020;2020:7371681. https:\/\/doi.org\/10.1155\/2020\/7371681.","journal-title":"J Parasitol Res"},{"key":"12130_CR31","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1186\/s12879-021-06018-6","volume":"21","author":"W Shibeshi","year":"2021","unstructured":"Shibeshi W, Alemkere G, Mulu A, Engidawork E. Efficacy and safety of artemisinin-based combination therapies for the treatment of uncomplicated malaria in pediatrics: a systematic review and meta-analysis. BMC Infect Dis. 2021;21:326. https:\/\/doi.org\/10.1186\/s12879-021-06018-6.","journal-title":"BMC Infect Dis"},{"key":"12130_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40268-018-0259-3","volume":"19","author":"S Whegang Youdom","year":"2019","unstructured":"Whegang Youdom S, Chiabi A, Basco LK. Monitoring the efficacy and safety of artemisinin-based combination therapies: a review and network meta-analysis of antimalarial therapeutic efficacy trials in Cameroon. Drugs RD. 2019;19:1\u201314. https:\/\/doi.org\/10.1007\/s40268-018-0259-3.","journal-title":"Drugs RD"},{"key":"12130_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s40249-017-0372-5","author":"A Mb","year":"2017","unstructured":"Mb A. Therapeutic efficacy of artemether-lumefantrine in the treatment of uncomplicated plasmodium falciparum malaria in Ethiopia: a systematic review and meta-analysis. Infect Dis Poverty. 2017, 6. https:\/\/doi.org\/10.1186\/s40249-017-0372-5.","journal-title":"Infect Dis Poverty"},{"key":"12130_CR34","doi-asserted-by":"publisher","first-page":"20","DOI":"10.4314\/ajid.v4i2.55149","volume":"4","author":"SO Bello","year":"2010","unstructured":"Bello SO, Chika A, Abdulgafar JO. Artesunate plus amodiaquine (AS+AQ) versus artemether -lumefantrine (AL) for the treatment of uncomplicated plasmodium falciparum malaria in sub-Saharan Africa-a meta-analysis. Afr J Infect Dis. 2010;4:20\u201328. https:\/\/doi.org\/10.4314\/ajid.v4i2.55149.","journal-title":"Afr J Infect Dis"},{"key":"12130_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2046-4053-4-1","volume":"4","author":"D Moher","year":"2015","unstructured":"Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4:1. https:\/\/doi.org\/10.1186\/2046-4053-4-1.","journal-title":"Syst Rev"},{"key":"12130_CR36","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan\u2014a web and mobile app for systematic reviews. Syst Rev. 2016;5:210. https:\/\/doi.org\/10.1186\/s13643-016-0384-4.","journal-title":"Syst Rev"},{"key":"12130_CR37","unstructured":"ACT Efficacy Africa. n.d. Accessed March 13, 2025. https:\/\/app.covidence.org\/reviews\/359664."},{"key":"12130_CR38","unstructured":"Study Quality Assessment Tools | NHLBI, NIH n.d. Accessed March 13, 2025. https:\/\/www.nhlbi.nih.gov\/health-topics\/study-quality-assessment-tools."},{"key":"12130_CR39","doi-asserted-by":"publisher","first-page":"f4040","DOI":"10.1136\/bmj.f4040","volume":"346","author":"P Sedgwick","year":"2013","unstructured":"Sedgwick P. Meta-analyses: heterogeneity and subgroup analysis. BMJ. 2013;346:f4040. https:\/\/doi.org\/10.1136\/bmj.f4040.","journal-title":"BMJ"},{"key":"12130_CR40","doi-asserted-by":"publisher","first-page":"e0264339","DOI":"10.1371\/journal.pone.0264339","volume":"17","author":"K Marwa","year":"2022","unstructured":"Marwa K, Kapesa A, Baraka V, Konje E, Kidenya B, Mukonzo J, et al. Therapeutic efficacy of artemether-lumefantrine, artesunate-amodiaquine and dihydroartemisinin-piperaquine in the treatment of uncomplicated plasmodium falciparum malaria in Sub-Saharan Africa: a systematic review and meta-analysis. PLoS One. 2022;17:e0264339. https:\/\/doi.org\/10.1371\/journal.pone.0264339.","journal-title":"PLoS One"},{"key":"12130_CR41","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1186\/1475-2875-8-203","volume":"8","author":"J Zwang","year":"2009","unstructured":"Zwang J, Olliaro P, Barennes H, Bonnet M, Brasseur P, Bukirwa H, et al. Efficacy of artesunate-amodiaquine for treating uncomplicated falciparum malaria in sub-Saharan Africa: a multi-centre analysis. Malar J. 2009;8:203. https:\/\/doi.org\/10.1186\/1475-2875-8-203.","journal-title":"Malar J"},{"key":"12130_CR42","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.trstmh.2008.03.024","volume":"102","author":"A Ogbonna","year":"2008","unstructured":"Ogbonna A, Uneke CJ. Artemisinin-based combination therapy for uncomplicated malaria in sub-Saharan Africa: the efficacy, safety, resistance and policy implementation since Abuja 2000. Trans R Soc Trop Med Hyg. 2008;102:621\u201327. https:\/\/doi.org\/10.1016\/j.trstmh.2008.03.024.","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"12130_CR43","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1093\/femsre\/fuw037","volume":"41","author":"CJ Woodrow","year":"2017","unstructured":"Woodrow CJ, White NJ. The clinical impact of artemisinin resistance in Southeast Asia and the potential for future spread. FEMS Microbiol Rev. 2017;41:34\u201348. https:\/\/doi.org\/10.1093\/femsre\/fuw037.","journal-title":"FEMS Microbiol Rev"},{"key":"12130_CR44","doi-asserted-by":"publisher","first-page":"e77634","DOI":"10.7554\/eLife.77634","volume":"11","author":"T Masserey","year":"2022","unstructured":"Masserey T, Lee T, Golumbeanu M, Shattock AJ, Kelly SL, Hastings IM, et al. The influence of biological, epidemiological, and treatment factors on the establishment and spread of drug-resistant plasmodium falciparum. eLife. 2022;11:e77634. https:\/\/doi.org\/10.7554\/eLife.77634.","journal-title":"eLife"},{"key":"12130_CR45","doi-asserted-by":"publisher","first-page":"a025619","DOI":"10.1101\/cshperspect.a025619","volume":"7","author":"D Menard","year":"2017","unstructured":"Menard D, Dondorp A. Antimalarial drug resistance: a threat to malaria elimination. Cold Spring Harb Perspect Med. 2017;7:a025619. https:\/\/doi.org\/10.1101\/cshperspect.a025619.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"12130_CR46","doi-asserted-by":"publisher","unstructured":"Balmer AJ, White NF, \u00dcnl\u00fc ES, Lee C, Pearson RD, Almagro-Garcia J, et al. Understanding the global rise of artemisinin resistance: insights from over 100,000 plasmodium falciparum samples. eLife. n.d;14:e105544. https:\/\/doi.org\/10.7554\/eLife.105544.","DOI":"10.7554\/eLife.105544"},{"key":"12130_CR47","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1056\/NEJMoa2101746","volume":"385","author":"B Balikagala","year":"2021","unstructured":"Balikagala B, Fukuda N, Ikeda M, Katuro OT, Tachibana S-I, Yamauchi M, et al. Evidence of artemisinin-resistant malaria in Africa. N Engl J Med. 2021;385:1163\u201371. https:\/\/doi.org\/10.1056\/NEJMoa2101746.","journal-title":"N Engl J Med"},{"key":"12130_CR48","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12936-019-2730-1","volume":"18","author":"DS Ishengoma","year":"2019","unstructured":"Ishengoma DS, Mandara CI, Francis F, Talundzic E, Lucchi NW, Ngasala B, et al. Efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated malaria and prevalence of Pfk13 and Pfmdr1 polymorphisms after a decade of using artemisinin-based combination therapy in mainland Tanzania. Malar J. 2019;18:88. https:\/\/doi.org\/10.1186\/s12936-019-2730-1.","journal-title":"Malar J"},{"key":"12130_CR49","doi-asserted-by":"publisher","first-page":"e37166","DOI":"10.1371\/journal.pone.0037166","volume":"7","author":"RJ Maude","year":"2012","unstructured":"Maude RJ, Socheat D, Nguon C, Saroth P, Dara P, Li G, et al. Optimising strategies for plasmodium falciparum malaria elimination in Cambodia: primaquine, mass drug administration and artemisinin resistance. PLoS One. 2012;7:e37166. https:\/\/doi.org\/10.1371\/journal.pone.0037166.","journal-title":"PLoS One"},{"key":"12130_CR50","doi-asserted-by":"publisher","first-page":"e0002200","DOI":"10.1371\/journal.pgph.0002200","volume":"3","author":"TD Nguyen","year":"2023","unstructured":"Nguyen TD, Tran T-A, Parker DM, White NJ, Boni MF. Antimalarial mass drug administration in large populations and the evolution of drug resistance. PLoS Glob Public Health. 2023;3:e0002200. https:\/\/doi.org\/10.1371\/journal.pgph.0002200.","journal-title":"PLoS Glob Public Health"},{"key":"12130_CR51","doi-asserted-by":"publisher","first-page":"e0268095","DOI":"10.1371\/journal.pone.0268095","volume":"17","author":"M Ocan","year":"2022","unstructured":"Ocan M, Ashaba FK, Mwesigwa S, Edgar K, Kamya MR, Nsobya SL. Prevalence of arps10, fd, pfmdr-2, pfcrt and pfkelch13 gene mutations in Plasmodium falciparum parasite population in Uganda. PLoS One. 2022;17:e0268095. https:\/\/doi.org\/10.1371\/journal.pone.0268095.","journal-title":"PLoS One"},{"key":"12130_CR52","doi-asserted-by":"publisher","first-page":"e66277","DOI":"10.7554\/eLife.66277","volume":"10","author":"BH Stokes","year":"2021","unstructured":"Stokes BH, Dhingra SK, Rubiano K, Mok S, Straimer J, Gn\u00e4dig NF, et al. Plasmodium falciparum K13 mutations in Africa and Asia impact artemisinin resistance and parasite fitness. eLife. 2021;10:e66277. https:\/\/doi.org\/10.7554\/eLife.66277.","journal-title":"eLife"},{"key":"12130_CR53","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/ng.3189","volume":"47","author":"O Miotto","year":"2015","unstructured":"Miotto O, Amato R, Ashley EA, MacInnis B, Almagro-Garcia J, Amaratunga C, et al. Genetic architecture of artemisinin-resistant plasmodium falciparum. Nat Genet. 2015;47:226\u201334. https:\/\/doi.org\/10.1038\/ng.3189.","journal-title":"Nat Genet"},{"key":"12130_CR54","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1186\/s12936-022-04330-3","volume":"21","author":"T Kampoun","year":"2022","unstructured":"Kampoun T, Srichairatanakool S, Prommana P, Shaw PJ, Green JL, Knuepfer E, et al. Apicoplast ribosomal protein S10-V127M enhances artemisinin resistance of a Kelch13 transgenic plasmodium falciparum. Malar J. 2022;21:302. https:\/\/doi.org\/10.1186\/s12936-022-04330-3.","journal-title":"Malar J"},{"key":"12130_CR55","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12936-016-1663-1","volume":"16","author":"B Balikagala","year":"2017","unstructured":"Balikagala B, Mita T, Ikeda M, Sakurai M, Yatsushiro S, Takahashi N, et al. Absence of in vivo selection for K13 mutations after artemether\u2013lumefantrine treatment in Uganda. Malar J. 2017;16:23. https:\/\/doi.org\/10.1186\/s12936-016-1663-1.","journal-title":"Malar J"},{"key":"12130_CR56","doi-asserted-by":"publisher","first-page":"14216","DOI":"10.1073\/pnas.0804628105","volume":"105","author":"MF Boni","year":"2008","unstructured":"Boni MF, Smith DL, Laxminarayan R. Benefits of using multiple first-line therapies against malaria. Proc Natl Acad Sci U S A. 2008;105:14216\u201321. https:\/\/doi.org\/10.1073\/pnas.0804628105.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"12130_CR57","unstructured":"Multiple first-line therapies as part of the response to antimalarial drug resistance. n.d. https:\/\/www.who.int\/publications\/i\/item\/9789240103603. accessed March 10, 2025."},{"key":"12130_CR58","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1093\/infdis\/jiu540","volume":"211","author":"B Coulibaly","year":"2015","unstructured":"Coulibaly B, Pritsch M, Bountogo M, Meissner PE, Nebi\u00e9 E, Klose C, et al. Efficacy and safety of triple combination therapy with artesunate-amodiaquine\u2013methylene blue for falciparum malaria in children: a randomized controlled trial in Burkina Faso. J Infect Dis. 2015;211:689\u201397. https:\/\/doi.org\/10.1093\/infdis\/jiu540.","journal-title":"The J Infect Dis"},{"key":"12130_CR59","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1186\/s12936-021-03845-5","volume":"20","author":"C Rasmussen","year":"2021","unstructured":"Rasmussen C, Ringwald P. Is there evidence of anti-malarial multidrug resistance in Burkina Faso? Malar J. 2021;20:320. https:\/\/doi.org\/10.1186\/s12936-021-03845-5.","journal-title":"Malar J"},{"key":"12130_CR60","doi-asserted-by":"publisher","first-page":"e01080","DOI":"10.1128\/JCM.01080-19","volume":"58","author":"C Kamaliddin","year":"2019","unstructured":"Kamaliddin C, Joste V, Hubert V, Kendjo E, Argy N, Houze S. Evaluation of pcr to monitor plasmodium falciparum treatment efficacy in a nonendemicity setting. J Clin Microbiol. 2019;58:e01080\u201319. https:\/\/doi.org\/10.1128\/JCM.01080-19.","journal-title":"J Clin Microbiol"},{"key":"12130_CR61","unstructured":"Methods and techniques for clinical trials on antimalarial drug efficacy: genotyping to identify parasite populations. n.d. https:\/\/www.who.int\/publications\/i\/item\/9789241596305. accessed March 14, 2025."},{"key":"12130_CR62","doi-asserted-by":"publisher","first-page":"e20","DOI":"10.1016\/S1473-3099(19)30426-8","volume":"20","author":"I Felger","year":"2020","unstructured":"Felger I, Snounou G, Hastings I, Moehrle JJ, Beck H-P. Pcr correction strategies for malaria drug trials: updates and clarifications. Lancet Infect Dis. 2020;20:e20\u20135. https:\/\/doi.org\/10.1016\/S1473-3099(19)30426-8.","journal-title":"Lancet Infect Dis"},{"key":"12130_CR63","doi-asserted-by":"publisher","first-page":"195","DOI":"10.3390\/tropicalmed8040195","volume":"8","author":"JMT Kabor\u00e9","year":"2023","unstructured":"Kabor\u00e9 JMT, Siribi\u00e9 M, Hien D, Soulama I, Barry N, Baguiya A, et al. Feasibility and acceptability of a strategy deploying multiple first-line artemisinin-based combination therapies for uncomplicated malaria in the health district of Kaya, Burkina Faso. Trop Med Infect Dis. 2023;8:195. https:\/\/doi.org\/10.3390\/tropicalmed8040195.","journal-title":"Trop Med Infect Dis"},{"key":"12130_CR64","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3390\/tropicalmed9050093","volume":"9","author":"C Audibert","year":"2024","unstructured":"Audibert C, Aspinall A, Tchouatieu A-M, Hugo P. Evaluation of segmentation, rotation, and geographic delivery approaches for deployment of multiple first-line treatment (MFT) to respond to antimalarial drug resistance in Africa: a qualitative study in seven sub-sahara countries. Trop Med Infect Dis. 2024;9:93. https:\/\/doi.org\/10.3390\/tropicalmed9050093.","journal-title":"Trop Med Infect Dis"},{"key":"12130_CR65","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s12936-019-2756-4","volume":"18","author":"D Leroy","year":"2019","unstructured":"Leroy D, Macintyre F, Adoke Y, Ouoba S, Barry A, Mombo-Ngoma G, et al. African isolates show a high proportion of multiple copies of the plasmodium falciparum plasmepsin-2 gene, a piperaquine resistance marker. Malar J. 2019;18:126. https:\/\/doi.org\/10.1186\/s12936-019-2756-4.","journal-title":"Malar J"},{"key":"12130_CR66","doi-asserted-by":"publisher","first-page":"e0151565","DOI":"10.1371\/journal.pone.0151565","volume":"11","author":"P Sondo","year":"2016","unstructured":"Sondo P, Derra K, Diallo Nakanabo S, Tarnagda Z, Kazienga A, Zampa O, et al. Artesunate-amodiaquine and artemether-lumefantrine therapies and selection of Pfcrt and Pfmdr1 alleles in Nanoro, Burkina Faso. PLoS One. 2016;11:e0151565. https:\/\/doi.org\/10.1371\/journal.pone.0151565.","journal-title":"PLoS One"},{"key":"12130_CR67","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s12936-023-04574-7","volume":"22","author":"CO Falade","year":"2023","unstructured":"Falade CO, Orimadegun AE, Olusola FI, Michael OS, Anjorin OE, Funwei RI, et al. Efficacy and safety of pyronaridine\u2013artesunate versus artemether\u2013lumefantrine in the treatment of acute uncomplicated malaria in children in South-West Nigeria: an open-labelled randomized controlled trial. Malar J. 2023;22:154. https:\/\/doi.org\/10.1186\/s12936-023-04574-7.","journal-title":"Malar J"},{"key":"12130_CR68","doi-asserted-by":"publisher","first-page":"e0020722","DOI":"10.1128\/aac.00207-22","volume":"66","author":"N Westercamp","year":"2022","unstructured":"Westercamp N, Owidhi M, Otieno K, Chebore W, Buff AM, Desai M, et al. Efficacy of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated plasmodium falciparum malaria among children in Western Kenya, 2016 to 2017. Antimicrob Agents Chemother. 2022;66:e0020722. https:\/\/doi.org\/10.1128\/aac.00207-22.","journal-title":"Antimicrob Agents Chemother"},{"key":"12130_CR69","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1186\/s12936-024-05088-6","volume":"23","author":"KM Oyebola","year":"2024","unstructured":"Oyebola KM, Ligali FC, Owoloye AJ, Aina OO, Alo YM, Erinwusi B, et al. Assessing the therapeutic efficacy of artemether-lumefantrine for uncomplicated malaria in Lagos, Nigeria: a comprehensive study on treatment response and resistance markers. Malar J. 2024;23:261. https:\/\/doi.org\/10.1186\/s12936-024-05088-6.","journal-title":"Malar J"},{"key":"12130_CR70","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1016\/S1473-3099(20)30929-4","volume":"21","author":"M Hamaluba","year":"2021","unstructured":"Hamaluba M, van der PR, Weya J, Njuguna P, Ngama M, Kalume P, et al. Arterolane\u2013piperaquine\u2013mefloquine versus arterolane\u2013piperaquine and artemether\u2013lumefantrine in the treatment of uncomplicated plasmodium falciparum malaria in Kenyan children: a single-centre, open-label, randomised, non-inferiority trial. Lancet Infect Dis. 2021;21:1395\u2013406. https:\/\/doi.org\/10.1016\/S1473-3099(20)30929-4.","journal-title":"Lancet Infect Dis"},{"key":"12130_CR71","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1111\/tmi.12847","volume":"22","author":"M Warsame","year":"2017","unstructured":"Warsame M, Hassan AH, Hassan AM, Arale AM, Jibril AM, Mohamud SA, et al. Efficacy of artesunate + sulphadoxine\/pyrimethamine and artemether + lumefantrine and dhfr and dhps mutations in Somalia: evidence for updating the malaria treatment policy. Trop Med Int Health TM IH. 2017;22:415\u201322. https:\/\/doi.org\/10.1111\/tmi.12847.","journal-title":"Trop Med Int Health TM IH"},{"key":"12130_CR72","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1186\/s12936-016-1339-x","volume":"15","author":"AA Adeel","year":"2016","unstructured":"Adeel AA, Elnour FAA, Elmardi KA, Abd-Elmajid MB, Elhelo MM, Ali MS, et al. High efficacy of artemether-lumefantrine and declining efficacy of artesunate + sulfadoxine-pyrimethamine against plasmodium falciparum in Sudan (2010\u20132015): evidence from in vivo and molecular marker studies. Malar J. 2016;15:285. https:\/\/doi.org\/10.1186\/s12936-016-1339-x.","journal-title":"Malar J"},{"key":"12130_CR73","unstructured":"Strategy to respond to antimalarial drug resistance in Africa n.d. Accessed March 14, 2025. https:\/\/www.who.int\/publications\/i\/item\/9789240060265."},{"key":"12130_CR74","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1111\/tmi.12458","volume":"20","author":"M Warsame","year":"2015","unstructured":"Warsame M, Hassan AM, Barrette A, Jibril AM, Elmi HH, Arale AM, et al. Treatment of uncomplicated malaria with artesunate plus sulfadoxine\u2013pyrimethamine is failing in Somalia: evidence from therapeutic efficacy studies and Pfdhfr and pfdhps mutant alleles. Trop Med Int Health. 2015;20:510\u201317. https:\/\/doi.org\/10.1111\/tmi.12458.","journal-title":"Trop Med Int Health"},{"key":"12130_CR75","doi-asserted-by":"publisher","first-page":"e39434","DOI":"10.1016\/j.heliyon.2024.e39434","volume":"10","author":"SA Hassan","year":"2024","unstructured":"Hassan SA, Mohamed Dirie A, Ahmed NR, Omar AI. Update on antimicrobial resistance in Somalia: current status, challenges, opportunities, and future perspectives. Heliyon. 2024;10:e39434. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e39434.","journal-title":"Heliyon"},{"key":"12130_CR76","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1186\/s12936-019-2864-1","volume":"18","author":"M Warsame","year":"2019","unstructured":"Warsame M, Hassan AM, Hassan AH, Jibril AM, Khim N, Arale AM, et al. High therapeutic efficacy of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated falciparum malaria in Somalia. Malar J. 2019;18:231. https:\/\/doi.org\/10.1186\/s12936-019-2864-1.","journal-title":"Malar J"},{"key":"12130_CR77","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1186\/s13104-020-05363-0","volume":"13","author":"NS Mohamed","year":"2020","unstructured":"Mohamed NS, Abdelbagi H, Osman HA, Ahmed AE, Yousif AM, Edris YB, et al. A snapshot of plasmodium falciparum malaria drug resistance markers in Sudan: a pilot study. BMC Res Notes. 2020;13:512. https:\/\/doi.org\/10.1186\/s13104-020-05363-0.","journal-title":"BMC Res Notes"},{"key":"12130_CR78","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s12936-020-03165-0","volume":"19","author":"AO Mohamed","year":"2020","unstructured":"Mohamed AO, Hussien M, Mohamed A, Suliman A, Elkando NS, Abdelbagi H, et al. Assessment of plasmodium falciparum drug resistance molecular markers from the Blue Nile State, Southeast Sudan. Malar J. 2020;19:78. https:\/\/doi.org\/10.1186\/s12936-020-03165-0.","journal-title":"Malar J"},{"key":"12130_CR79","doi-asserted-by":"publisher","unstructured":"Adam M, Nahzat S, Kakar Q, Assada M, Witkowski B, Tag Eldin Elshafie A, et al. Antimalarial drug efficacy and resistance in malaria-endemic countries in HANMAT-PIAM_net countries of the Eastern Mediterranean region 2016\u20132020: clinical and genetic studies. Trop Med Int Health n.d.;n\/a. https:\/\/doi.org\/10.1111\/tmi.13929.","DOI":"10.1111\/tmi.13929"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-12130-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-025-12130-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-12130-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T13:11:52Z","timestamp":1764594712000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-025-12130-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,25]]},"references-count":79,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["12130"],"URL":"https:\/\/doi.org\/10.1186\/s12879-025-12130-8","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,25]]},"assertion":[{"value":"9 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1684"}}